Augmentation of recombinant interleukin-2-dependent murine macrophage-mediated tumour cytotoxicity by recombinant tumour necrosis factor-alpha.
The activation of murine macrophages by recombinant human interleukin-2 (rH-IL-2) alone or in combination with recombinant human tumour necrosis factor-alpha (rH-TNF) was studied. Mouse peritoneal exudate macrophages were activated in vitro to the tumouricidal state. Macrophage treatment with rH-IL-2 alone slightly enhanced cytotoxic activity against B16 melanoma cells. Synergism was observed when macrophages were treated with rH-IL-2 and rH-TNF, either when applied sequentially or when both agents were given at the same time.
Kos
F J
FJ
Department of Pathology, Center of Oncology, Cracow, Poland.
D000818:Animals; D003602:Cytotoxicity, Immunologic / Q000187:drug effects / Q000276:immunology*; D004357:Drug Synergism; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology* / Q000502:physiology; D008262:Macrophage Activation / Q000187:drug effects*; D008264:Macrophages / Q000187:drug effects / Q000276:immunology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010529:Peritoneal Cavity / Q000166:cytology; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D007376:Interleukin-2; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha